Find Articles in:
All
Business
Reference
Technology
News
Lifestyle

Controversy spikes over anti-diabetes drug Avandia

AFP, June, 2007

WASHINGTON (AFP) — Controversy over diabetes drug Avandia heated up Wednesday as experts pointed to studies linking it to greater heart attack risk, while a GSK study claimed rosiglitazone is safe.

The GlaxoSmithKline study published online Tuesday by the New England Journal of Medicine (NEJM) gave preliminary results of a four-year clinical study of 4,446 patients showing Avandia did not increase the rate of heart attacks or death.

Among the sub-group of patients who took Avandia, 29 died from heart attacks, against 35 who died from a control group taking two other drugs for adult-onset, type 2 diabetes, GSK said in the study.

In a study that analyzed 42 clinical trials published May 21 by NJEM, eminent cardiologist Steven Nissen of the Cleveland Clinic, in...

 

BNET TalkbackShare your ideas and expertise on this topic

The following tags are supported in BNET comments:
<b></b> <i></i> <u></u> <pre></pre>

Leave a Reply

  1. You are currently a guest | Login?
advertisement
Go
advertisement
  • Click Here
  • Click Here
advertisement